Innate Pharma (IPHA) Change in Account Payables (2019 - 2025)
Historic Change in Account Payables for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to $13.6 million.
- Innate Pharma's Change in Account Payables rose 13986.89% to $13.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $14.9 million, marking a year-over-year increase of 14776.04%. This contributed to the annual value of -$1.1 million for FY2024, which is 7401.54% up from last year.
- Latest data reveals that Innate Pharma reported Change in Account Payables of $13.6 million as of Q2 2025, which was up 13986.89% from $17.1 million recorded in Q4 2024.
- Over the past 5 years, Innate Pharma's Change in Account Payables peaked at $32.7 million during Q4 2021, and registered a low of -$41.0 million during Q2 2021.
- Moreover, its 5-year median value for Change in Account Payables was $13.6 million (2025), whereas its average is -$5.4 million.
- As far as peak fluctuations go, Innate Pharma's Change in Account Payables plummeted by 3478.37% in 2022, and later skyrocketed by 13986.89% in 2025.
- Quarter analysis of 5 years shows Innate Pharma's Change in Account Payables stood at $32.7 million in 2021, then crashed by 34.78% to $21.3 million in 2022, then decreased by 14.1% to $18.3 million in 2023, then fell by 6.58% to $17.1 million in 2024, then dropped by 20.32% to $13.6 million in 2025.
- Its Change in Account Payables was $13.6 million in Q2 2025, compared to $17.1 million in Q4 2024 and -$34.2 million in Q2 2024.